However, the therapy has some drawbacks: HER2 expression in gastric cancer is only around 9–38%, the antibody shows high heterogeneity, the benefit is more evident in patients with high levels of HER2 expression, and there are different testing methods for HER2 measurement (2). This evidence concerns the gene ERBB2 and gastric cancer.